Fatigue in Multiple Sclerosis: A Review of the Exploratory and Therapeutic Potential of Non-Invasive Brain Stimulation

Samar S. Ayache 1,2*, Nicolas Serratrice 3,4, Georges N. Abi Lahoud 3,4 and Moussa A. Chalah 1,2*

1 EA4391 Excitabilité Nerveuse et Thérapeutique, Université Paris Est Créteil, Créteil, France, 2 Department of Clinical Neurophysiology, DMU RivT, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Créteil, France, 3 Department of Spine Surgery, Centre Médico Chirurgical Bizet, Paris, France, 4 Institut de la Colonne Vertébrale et des Neurosciences (ICVNS), Centre Médico Chirurgical Bizet, Paris, France

Fatigue is the most commonly reported symptom in patients with multiple sclerosis (MS). It is a worrisome, frequent, and debilitating manifestation that could occur at any time during the course of MS and in all its subtypes. It could engender professional, familial, and socioeconomic consequences and could severely compromise the patients’ quality of life. Clinically, the symptom exhibits motor, cognitive, and psychosocial facets. It is also important to differentiate between perceived or subjective self-reported fatigue and fatigability which is an objective measure of decrement in the performance of cognitive or motor tasks. The pathophysiology of MS fatigue is complex, and its management remains a challenge, despite the existing body of literature on this matter. Hence, unraveling its neural mechanisms and developing treatment options that target the latter might constitute a promising field to explore. A PubMed/Medline/Scopus search was conducted to perform this review which aims (a) to reappraise the available electrophysiological studies that explored fatigue in patients with MS with a particular focus on corticospinal excitability measures obtained using transcranial magnetic stimulation and (b) to assess the potential utility of employing neuromodulation (i.e., non-invasive brain stimulation techniques) in this context. A special focus will be put on the role of transcranial direct current stimulation and transcranial magnetic stimulation. We have provided some suggestions that will help overcome the current limitations in upcoming research.

Keywords: multiple sclerosis, fatigue, neuromodulation, corticospinal excitability, tDCS, TMS, tRNS
INTRODUCTION

Multiple sclerosis (MS) is one of the most common neurological diseases and a serious cause of disability in young adults. Its natural course is characterized by recurrent relapses and progressive functional decline (1). With disease evolution, patients could accumulate several neurological dysfunctions, including motor deficit, sensory dysfunction, and sphincter disorders, among others (2). In addition, they could suffer from several “silent” “non-motor” complications, such as fatigue, pain, emotional manifestations, and cognitive dysfunctions (3).

Over the last two decades, MS symptoms have preoccupied the scientific community, and tremendous efforts have been made to understand the reasons behind their development and the modalities of their treatments. Among these symptoms, fatigue constitutes a real enigma and has given rise to collective awareness. Although the last few years have shown a growing literature on the characterization, pathophysiology, and treatment of MS fatigue, this symptom continues to challenge the medical and research societies of its difficult-to-treat nature and its resistance to the available pharmacological solutions.

Hence, in this review, we will start with a definition of MS fatigue by highlighting the difference between fatigue and fatiguability. Then, we will give an overview of its underlying pathophysiological mechanisms. There will be particular focus on the application of the neurophysiological techniques in this domain. Afterward, we will address the place of non-invasive brain stimulation (NIBS) interventions in the treatment of this symptom.

FATIGUE IN MS

MS fatigue is very common; it could impact the lives of 75–90% of patients suffering from this disease (2, 4). It deeply affects their professional, social, and familial domains and could result in significant health costs and, therefore, should not be neglected (5, 6). For all these reasons, understanding this symptom and adopting novel therapeutic approaches have become more important than ever before.

To start, the definition of fatigue has been a source of confusion for several years. On the one hand, the terms “tiredness,” “malaise,” and “motor weakness” have been interchangeably used by patients to describe their fatigue; on the other hand, care providers have sometimes perceived fatigue as a lack of self-motivation. Toward the end of the 90s, a consensus was set by the MS Council for Clinical Practice Guidelines and has ended this debate (7). According to this council, MS fatigue corresponds to “a subjective lack of physical and/or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities.” Currently, it is recommended to adopt this definition as has been thoroughly discussed in Mills and Young’s study (8). In the same perspective of this definition, the intensity of MS fatigue is temperature-dependent in a way that hot or cold temperatures would worsen or alleviate fatigue, respectively. This aspect differentiates it from the “classical” tiredness encountered in healthy individuals.

In addition to the importance of setting a clear definition of fatigue, it is important to stress the difference between subjective or perceived self-reported fatigue and fatiguability. While the former reflects a subjective experience that is classically tested by self-administered questionnaires, the latter reflects a performance decrement during the execution of a task and is usually evaluated with various cognitive or physical exercises.

Fatigue is a multifaceted symptom and consists of three domains: the physical, psychosocial, and cognitive domains. Thus, when patients complain about fatigue, the clinician or researcher should understand whether they feel this fatigue in the three domains or whether it only concerns one domain, for instance, the cognitive one. For this reason, some of the self-rated questionnaires that have been developed to diagnose and follow up on this complaint included questions dedicated to the assessment of several aspects of MS fatigue. For instance, the Modified Fatigue Impact Scale (MFIS), one of the most widely used scales, includes 21 questions that examine the three facets of fatigue (i.e., the physical, psychosocial, and cognitive ones) (7). In a similar manner, the Fatigue Scale for Motor and Cognitive Functions includes 20 questions and assesses two dimensions of MS fatigue as its name implies (9). Other scales assess one dimension of fatigue (e.g., the physical dimension), such as the 9-item Fatigue Severity Scale, which is one of the first tools developed to be used in PwMS (10), while others such as the Visual Analog Scale [VAS, (11)] provide a global assessment of this symptom [For a review refer to (1)].

Moreover, when talking about MS fatigue, it is pertinent to distinguish between primary fatigue, which is related to disease-specific mechanisms, and secondary fatigue, which could rather be attributed to comorbidities (motor symptoms, psychiatric manifestations, other medical conditions, or treatments adverse events) (1).

SELECTION CRITERIA

Research was done following PRISMA guidelines using computerized databases (PubMed/MEDLINE, Scopus) (12). An independent review was conducted by two of the authors (SSA and MAC) in order to identify original research articles published in English and French languages at any time till November 2021. The following key terms were used: (“MS” OR “multiple sclerosis”) AND (“fatigue”) AND (“non-invasive brain stimulation” OR “NIBS” OR “transcranial magnetic stimulation” OR “TMS” OR “theta burst stimulation” OR “TBS” OR “motor evoked potential” OR “MEP” OR “cortical excitability” OR “corticospinal excitability” OR “intracortical inhibition” OR “intracortical facilitation” OR “silent period” OR “interhemispheric inhibition” OR “transcranial direct current stimulation” OR “tDCS” OR “transcranial random noise stimulation” OR “tRNS”). In order to look for additional sources, the bibliographical references of the retrieved articles were also scanned.
Clinical, neuropsychological, neuroanatomical, neuroimmune, and neurophysiological studies attempted to explore this multidimensional symptom. From a clinical perspective, the relationship between fatigue and physical disability appears to be inconsistent; MS fatigue seems to occur in all disease subtypes (4). From a neuropsychological viewpoint, fatigue could be associated with specific emotions, thoughts, and behaviors according to a cognitive-behavioral model proposed by van Kessel and Moss-Morris (13). In addition, this symptom could be associated with emotional factors, with which it may have bidirectional relationships and may share common biological substrates (14). In terms of neuroanatomy, inconsistencies exist regarding conventional measures (e.g., lesion load, global brain atrophy), but more advanced neuroimaging modalities (e.g., tractography, normal-appearing white matter, regional brain volumes and lesion load, brain activity, and functional connectivity at rest or during task performance) have unraveled a cortico-striato-thalamo-cortical loop related to MS fatigue (15–19). The exploration of neuroimmune and neuroendocrine axes has yielded scarce findings linking MS fatigue to some peripheral proinflammatory cytokines (20–22), while the relationship between this symptom and other outcomes were inconsistent [i.e., cerebrospinal fluid markers, orexin-A system, hypothalamus-pituitary-adrenal axis (20, 21, 23, 24), or absent peripheral T cell populations or markers of inflammation (25, 26)] [for reviews see (14)]. Finally, neurophysiology also constitutes a discipline that addresses MS fatigue in terms of pathophysiology and management as will be developed in the following sections.

NIBS TO EXPLORE AND MANAGE FATIGUE IN MS

Modulating the activity of brain regions and circuits continues to be a fascinating scientific field and a source of inspiration for researchers worldwide. The story began in the previous century when scientists first tested the impact of a weak electric current on the functioning of neural networks in animals and discovered that the application of a polarizing current on the scalp results in various effects on cortical activity. Afterward, much research has taken place across the world, and the fruit of this long investment has resulted in the development of the various NIBS techniques that we currently have at our disposal. Among these techniques, two are particularly interesting and have been the subject of many scientific investigations into different pathologies. The first is based on a famous law of biophysics—Faraday’s law (the law of electromagnetic induction)—, while the second rather uses a weak electric current. These are, respectively, the transcranial magnetic stimulation (TMS) and the transcranial direct current stimulation (tDCS) techniques (27–30).

Neurophysiology of Fatigue in MS Using NIBS

As stated previously, TMS finds its roots in an ancient law of biophysics—the Faraday law. In fact, this law paved the way for the development of what has now become the rescue solution to some crippling neuropsychiatric manifestations, such as depression and neuropathic pain (29). Briefly, Faraday demonstrated that making an electric current flow in a conductive element would induce a magnetic field; the latter could in its turn induce an electric field in another conductive element placed nearby. Hence, applying a magnetic field on the scalp would diffuse toward the underlying cortical networks and would stimulate the corresponding nervous fibers (29).

The first clinical development of TMS served for the study of pyramidal motor conductions, using the technique known as motor evoked potentials (MEP). Performing MEP remains the most common application of TMS (31). This technique uses unique shocks applied to the skull to stimulate the pyramidal cortical neurons and to the spine to activate the nerve roots. A surface electromyographic recording is made at the level of the muscles of interest and the parameters (i.e., latency and amplitude) of the evoked responses are generally measured. Central motor conduction time (CMCT) is another TMS parameter used in clinical settings and reflects the time the nerve impulses take to travel from the motor cortex to the spinal motor neurons. It could be measured by subtracting the MEP latency obtained from spinal magnetic stimulation (also known as peripheral motor conduction time) from TMS-evoked MEP latency (32). Its lengthening may arise from a degeneration or a demyelination affecting the fastest-conducting cortico-motoneuronal fibers (33). Prolonged MEP latency was found to be a significant predictor of fatigue severity (34) while CMCT seems to be unrelated to this symptom (35).

Apart from obtaining conventional MEP, TMS has other important applications such as studying cortical excitability, which assesses different processes of regulation and execution of motor commands using paradigms of single and double cortical pulses. The parameters measured (i.e., motor thresholds (MT), short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF), cortical silent period (CSP), interhemispheric inhibition (IHI), cerebello-cortical inhibition, among others) provide information on neuronal modulation circuits using well-characterized GABAergic, glutamatergic, or cholinergic neurotransmission (32, 33). Excitability paradigms have been widely used to examine the pathophysiological processes behind several neurological and psychiatric symptoms, among which stands MS fatigue.

To start, concerning single-pulse parameters, no correlation was found between fatigue severity and resting MT (rMT) (36, 37), a parameter that reflects the excitability of the corticomotor neuronal membrane, including the spinal level. It corresponds to the stimulation intensity, as a percentage of the maximal stimulator output, that yields MEP of at least 50 µV amplitude on a fully relaxed muscle in 5 out of 10 trials (32, 33). The CSP is another single-pulse parameter that reflects
cortical (GABA-B) and spinal inhibitions (e.g., Renshaw cells, IA inhibitory interneurons) (32, 33). It could last up to 300 ms and corresponds to the interruption of voluntary muscular activity in a muscle of interest by applying a TMS pulse over the contralateral motor cortex. Prolonged CSP was found to be associated with fatigue severity in one study (38) but not in another one (37). Such discrepancy could be related to the clinical and methodological differences between both studies, such as the cohorts’ disease characteristics (predominantly relapsing–remitting vs. progressive disease, respectively) and the adapted fatigue measures (VAS vs. MFIS, respectively).

Besides single-pulse measures, double-pulse measures could also be used. Some of them consist of applying a first subthreshold conditioning stimulus (whose intensity is below the rMT) that would inhibit or facilitate the response of a second suprathreshold stimulus (whose intensity is above the rMT) delivered to the same cortical site depending on the interstimulus interval (ISI) (32). For instance, applying short (≤6 ms) and long (>7 ms) ISI could yield SICI and ICF which respectively, reflects GABA-A and glutamatergic transmissions. IHI represents another double-pulse measure that consists of conditioning the response of a suprathreshold stimulus by applying a suprathreshold stimulus over the contralateral motor site, and reflects GABAergic transcallosal activity (32). Three works have explored SICI in the context of MS fatigue and found low (36), high (37), or similar (39) pattern of inhibition in fatigued PwMS compared to non-fatigued PwMS and/or healthy controls (HC). In addition, in these three works, no significant group difference (or correlation) was obtained in terms of fatigue and ICF. Moreover, one of the three works included an IHI assessment and found no correlation between this measure and fatigue severity (37).

Some studies also explored the neurophysiological correlates of MS fatigue during motor task performance and tested the relationship of this symptom with movement preparation or execution phases. Some reported positive findings linking MS fatigue to movement-related TMS outcomes. Premovement MEP facilitation which is a normal finding following a motor task was found to be significantly reduced in fatigued PwMS compared to their non-fatigued counterparts and HC (39–41). This finding was correlated with frontal lesion load (39), motor performance decay [decrease in movement rate, (40)], and fatigue severity (39), suggesting a relationship between MS fatigue and abnormalities involving cerebral networks devoted to movement preparation. In addition, higher MEP amplitude was observed with contralateral hand grip following the fatiguing task in HC and non-fatigued PwMS but not in fatigued PwMS. This finding might suggest an involvement of callosal dysfunction in MS fatigue (42). Moreover, fatigue severity seems to be correlated with the time required for the rMT to reach the pre-exercise level (36). Conversely, no group difference in post-exercise MEP facilitation was found between non-fatigued and fatigued PwMS (43).

The second other major application of TMS is the realization of repetitive TMS (rTMS). Briefly, this method consists of delivering trains of stimulation at various frequencies and requiring specific machines (27, 29). Data on rTMS effects derive from numerous studies performed in healthy individuals, in whom low and high frequency (LF and HF) rTMS, respectively, led to reduction and augmentation of MEP size. Hence, LF-rTMS and HF-rTMS have been perceived as inhibitory and facilitatory interventions. However, this viewpoint is simplistic, and it is now known that this dichotomy is no more valid since rTMS effects also depend on the baseline excitatory state of the nervous circuits; a state that would vary between individuals and even in the same subject at different moments of the day, it would also vary between healthy networks and those affected by various pathologies. Even more, several studies have documented that the augmentation/reduction of MEP amplitude after the application of HF/LF rTMS over the precentral cortex [i.e., the primary motor cortex (M1)] may be due to a decrease/increase of the GABA mediated inhibitory control of the corticospinal circuit rather than a direct modulation of the motor cortex excitability. Thus, what is perceived as “facilitatory” protocol (HF rTMS) could be in fact “inhibitory” (decrease in the functioning of the GABA interneurons) and vice versa. Other factors that can impact rTMS effects include age, drugs, and genetic factors, among others [For review, please refer to (27)].

In addition to the “classical” rTMS paradigms, a particular form of rTMS has been recently developed, the so-called theta burst stimulation (TBS). It consists of applying bursts (three pulses per burst at 50 Hz) in a repetitive manner at theta frequency (at 5 Hz) (44). TBS could induce changes in corticospinal excitability and the nature of such changes depends on the way the bursts are applied. Continuous and intermittent TBS (cTBS and iTBS) could lead to long-term depression-like and long-term potentiation-like effects, respectively (44).

Concerning rTMS and MS fatigue pathophysiology, it is worth noting here that some study protocols have tested the effects of 5-Hz rTMS over MEP outcomes in PwMS. In one study, MEP outcomes did not significantly differ between fatigued and non-fatigued PwMS, with both patient groups showing an increase in MEP amplitude following the intervention (39). In another study, the expected increase in MEP size was not obtained in fatigued PwMS, an increment that was found in their non-fatigued counterparts and in HC (45). Methodological differences could partly account for the observed changes as the second study included an attentional task (instructions to focus attention on the hand corresponding to stimulation); in addition, as aforementioned, inter-individual variability in terms of the baseline cortical excitability level could be behind such a discrepancy. One should note that the second study also assessed the impact of paired-associative stimulation (peripheral nerve stimulation followed by 5-Hz rTMS) on MEP amplitude and yielded similar findings (i.e., no change in MEP amplitude in fatigued PwMS) (45).

As for TBS, it is worth mentioning that no single study has applied this technique to explore the underlying mechanisms of MS fatigue. Its future application in this context could unveil additional mechanisms incriminated in the generation of this symptom. Table 1 summarizes the neurophysiological studies that explored MS fatigue.

**Treatment of Fatigue in MS Using NIBS**
As stated previously, MS fatigue is perceived as a multidimensional construct, thus its management requires a
### TABLE 1 | Summary of studies on neurophysiological parameters in MS fatigue.

| Participants | Neurophysiological parameters | Other parameters | Results |
|--------------|-------------------------------|------------------|---------|
| Colombo et al. (46) | 30 PwMS (15 non-fatigued and 15 fatigued, FSS) Immunomodulant/immunosuppressive drugs: None | MEP of the four limbs | Disability: EDSS Function: Pyramidal functional system score Depression: MADRS |
| Petajan and White (42) | 32 PwMS (Classified according to presence or absence of upper extremities weakness) Immunomodulant/immunosuppressive drugs: not provided 10 HC | Evaluation before and after fatiguing exercise of resting and facilitated MEP using TMS (abductor pollicus brevis and flexor carpi radialis) | Exercise-induced changes in energy metabolism (phosphocreatine) measured using 31P magnetic resonance spectroscopy in flexor carpi radialis |
| Romani et al. (47) | 60 PwMS (20 fatigued and 40 fatigued, fatigued having FSS scores above the 75th of a previous sample) Immunomodulant/immunosuppressive drugs: None | Evaluation before and after 8-week treatment with 4-aminopyridine and fluoxetine (no placebo control); Somatosensory evoked potentials, TMS, muscle fatigability | Other fatigue measures: FIS Depression: HDRS, BDI Disability: EDSS |
| Peretti et al. (43) | 41 PwMS (9 non-fatigued and 32 fatigued Immunomodulant/immunosuppressive drugs: all receiving interferon beta-1a 13 HC | MEP at rest, post-exercise MEP facilitation (PEF), and post-exercise MEP depression (PED) | Reduction in MEP (depression) following fatigue onset in HC but not in PwMS No group difference in post-exercise MEP findings (facilitation) between non-fatigued and fatigued PwMS |
| Liepert et al. (36) | 16 PwMS (8 fatigued and 8 non-fatigued based on FSS (fatigued had FSS ≥4) Immunomodulant/immunosuppressive drugs: not provided 6 HC | rMT SICI ICF Three-time measurements in relation to an exercise (repeating hand grip); pre-exercise, postexercise (when rMT was back to the postexercise level), and 15 min later CMAP of the abductor pollicis brevis (following median nerve stimulation) Before and after exercise | At baseline: SICI was lower in fatigued PwMS compared to the other groups After exercise: SICI remained lower in the fatigued group in comparison with their non-fatigued counterparts and HC Fatigue severity correlated with the time required for the rMT to reach the pre-exercise level |

(Continued)
| Participants | Neurophysiological parameters | Other parameters | Results |
|--------------|--------------------------------|-----------------|---------|
| Santarnecci et al. ([48]) | 10 PwMS (fatigue measured using FSS and FIS but not classified according to fatigue scores was performed) Imunomodulant/immunosuppressive drugs: 5 patients receiving β-interferon 10 HC | CSP recorded at the first dorsal interosseus muscle and at the abductor digiti minimi muscle at baseline and after a fatiguing tapping task CSP and fatigue changes before and after chronic amantadine therapy in PwMS | Sleep: ESS Anxiety: Hamilton scale for anxiety Depression: HDRS and BDI Prior to amantadine therapy: shorter CSP in PwMS vs. HC at baseline and contrasting pattern of CSP changes following fatiguing task in PwMS (increase) and in HC (decrease) After amantadine therapy: • Significant improvement in FSS and marginal improvement in FIS • Normalization of CSP duration in PwMS • Correlation between CSP changes and fatigue improvement (only with FIS, only in the first dorsal interosseus muscle). |
| Morgante et al. ([39]) | 33 PwMS (17 non-fatigued and 16 fatigued, fatigued had FSS > 4) Immunomodulant/immunosuppressive drugs: 32 patients receiving treatments 12 HC | MRI: lesion load TMS: CMCT, SICI, ICF, pre-movement facilitation, and effect of short trains of 5-Hz repetitive TMS | Depression: HDRS No significant group differences in depression scores Higher frontal lobe LL in fatigued PwMS No significant group difference in SICI/ICF Absence of MEP size increase following repetitive TMS in PwMS compared to HC Lack of pre-movement facilitation in fatigued PwMS vs. non-fatigued PwMS and HC Correlation between pre-movement facilitation abnormalities, frontal LL, and fatigue severity |
| Scheidegger et al. ([49]) | 23 PwMS Immunomodulant/immunosuppressive drugs: 14 patients receiving the treatment 13 HC | TMS: CMCT by means of the triple stimulation protocol and obtaining central conduction index (CCI) during a fatiguing exercise of the abductor digiti minimi (2 min) followed by recovery (7 min) | No significant group difference in force decline following exercise Less marked CCI decline in PwMS compared to HC No correlation between fatigue scores and CCI or force drop Reduction of correct sequences and the ability to keep a fixed movement rate in fatigued vs. non-fatigued PwMS as well as HC Reduction of post-exercise PMF among fatigued PwMS Correlation between PMF abnormalities and performance decay |
| Russo et al. ([40]) | 24 PwMS (12 non-fatigued and 12 fatigued; fatigued had FSS > 36) Immunomodulant/immunosuppressive drugs: information not provided 10 HC | Motor cortex excitability and the premovement facilitation (PMF) before and after the finger-tapping task | No significant group difference in force decline following exercise Less marked CCI decline in PwMS compared to HC No correlation between fatigue scores and CCI or force drop Reduction of correct sequences and the ability to keep a fixed movement rate in fatigued vs. non-fatigued PwMS as well as HC Reduction of post-exercise PMF among fatigued PwMS Correlation between PMF abnormalities and performance decay |
| Thickbroom et al. ([50]) | 10 PwMS Immunomodulant/immunosuppressive drugs: 9 patients receiving β-interferon 13 HC | MEP amplitudes before and after each cycle of a foot-tapping task Five cycles of 15 s-foot tapping task followed by 45 min rest period: maximum voluntary contraction of ankle dorsiflexion (at baseline and immediately after the completion of the task) Number of taps Inter tap interval | Increase in MEP amplitudes following exercise in both groups, but more important in PwMS Maximal voluntary contraction is lower in PwMS vs. HC. Decreased maximal voluntary contraction after exercise in both groups but more important in PwMS. No difference was found in the tapping rate. |
TABLE 1 | Continued

| Participants | Neurophysiological parameters | Other parameters | Results |
|--------------|-------------------------------|------------------|---------|
| Conte et al. (45) | 25 PwMS (13 non-fatigued and 12 fatigued based on MRI (i.e., details NP) Immunomodulant/immunosuppressive drugs: patients receiving treatment (without further information) 18 HC | Experimental conditions (relaxed vs. attention): 5-Hz repetitive TMS and paired associative stimulation while focusing attention on the hand contralateral to the stimulated motor cortex | Absence of attention-induced MEP increase using both techniques in fatigued PwMS compared to non-fatigued patients. Correlation between attention-induced repetitive-TMS related changes and fatigue severity (mostly physical subscale). |
| Russo et al. (41) | 30 PwMS (non-fatigued and fatigued based on FSS (i.e., fatigued patients had FSS $\geq 4$) Immunomodulant/immunosuppressive drugs: information not provided | Pre movement facilitation DTI study | Significant difference in premovement facilitation between fatigued and non-fatigued groups. Significant correlation between fatigue scores and mean diffusivity in bilateral fronto-thalamic connections. |
| Chaves et al. (51) | 82 PwMS Immunomodulant/immunosuppressive drugs: 47 patients receiving treatment | Bilateral aMT and rMT Then ratios were calculated between weaker and stronger side aMT and rMT (Weaker and stronger sides were defined according to performance on pinch and hand grip) | Disability: EDSS Dexterity: 9HPT Cognition: SDMT Walking speed: instrumented walkway Heat sensitivity: VAS Fatigue: VAS Pain: VAS Subjective impact of MS: MSIS-29 |
| Chaves et al. (38) | 82 PwMS Immunomodulant/immunosuppressive drugs: 48 patients receiving treatment | Bilateral aMT, rMT and CSP | Fatigue: VAS Exercise test inflammatory cytokines: TNF |
| Mordillo-Mateos et al. (35) | 17 PwMS Immunomodulant/immunosuppressive drugs: 11 patients receiving treatment 16 HC | CMAP and F wave of right and left first dorsal interosseous muscles (after ulnar nerve stimulation) rMT, MEP amplitude latency (at 120% rMT) and CMCT of above-mentioned muscles These parameters were measured before, immediately, one and two minutes after the fatiguing task | At baseline: lower CMAP and MEP, higher rMT, longer CMCT and higher fatigue scores in PwMS compared to HC Task performance: lesser handgrip strength in PwMS compared to HC In PwMS, fatigue shown to be independent from handgrip strength; fatigue shown to be independent from CMCT. |
| Chalah et al. (37) | 38 PwMS [17 non-fatigued and 21 fatigued based on MRI (i.e., Fatigued: MFIS $\geq 45$) Immunomodulant/immunosuppressive drugs: 19 patients receiving treatment | rMT CSP SICI ICF IHI | Neuropsychological parameters: Anxiety and Depression: HADS Excessive Daytime sleepiness: ESS Cognition: SDMT Alexithymia: TAS Neuroradiological measures (Volume based morphometry) |

(Continued)
| Participants | Neurophysiological parameters | Other parameters | Results |
|--------------|-------------------------------|-----------------|---------|
| Coates et al. (34) 26 PwMS (13 non-fatigued and 13 fatigued based on FSS (i.e., fatigued: FSS ≥ 4 and MFIS ≥ 34)) Immunomodulant/immunosuppressive drugs: some patients receiving treatment (without further information) 13 HC | Central parameters: MEP amplitude and latency, CSP Peripheral parameters: femoral nerve electrical stimulation Measured at baseline and every 3 min throughout cycling during of a step test until reaching volitional exhaustion | Clinical parameters: Depression: CES-D Sleep quality: PSQI Quality of life: MSQoL-54 Perceived activity level: GLTEQ Peripheral pro-inflammatory cytokines Axial panoramic ultrasound for knee extensor cross-sectional area, actigraphy (sleep and rest-activity cycles) | Significant worse depression, sleep and quality of life scores in fatigued PwMS compared to the other groups; no group difference in actigraphy, maximal aerobic capacity and perceived activity level Higher interleukin 8 in fatigued PwMS compared to HC During cycling: No time or interaction effect was observed for MEP amplitude or latency. Reduction in CSP compared to baseline in fatigued PwMS compared to the other groups At volitional exhaustion: • Reduced MEP amplitudes and prolonged MEP latencies in fatigued PwMS; loss of group differences in CSP • Higher decline in maximal voluntary contraction force and potentiated twitch force in fatigued PwMS Regression analysis: Prolonged MEP latency, increased peripheral muscle fatigability and depression scores were significant predictors of fatigue severity |

aMT, active Motor Threshold; BDI, Beck Depression Inventory; BRPES, Borg Rating of Perceived Exertion Scale; CES-D, Center for Epidemiologic Studies Depression Scale; CMAP, compound Motor Action Potential; CMCT, Central Motor Conduction Time; CSP, cortical silent period; DTI, Diffuse Tensor Imaging; EDSS, Expanded Disease Severity Scale; ESS, Epworth Sleepiness Scale; FSS, Fatigue Severity Scale; GLTEQ, Godin-Leisure-Time Exercise Questionnaire; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; 9HPT, Nine Hole Peg Test; HC, Healthy Controls; IHI, Interhemispheric Inhibition; ICF, Intracortical Facilitation; MEP, Motor Evoked Potential; MFIS, Modified Fatigue Impact Scale; MSIS 29, Multiple Sclerosis Impact Scale; MSQoL-54, Multiple Sclerosis Quality of Life-54; MS, Multiple Sclerosis; PSQI, Pittsburgh Sleep Quality Index; PwMS, Patients with Multiple Sclerosis; rMT, resting Motor Threshold; SDMT, Symbol Digit Modalities Test; SICI, Short-Interval intracortical Inhibition; TAS, Toronto Alexithymia Scale; TMS, Transcranial Magnetic Stimulation; TNF, Tumor Necrosis Factor; VAS, Visual Analog Scale.
A personalized strategy that should address each of its dimensions. In this setting, various therapeutic interventions have been tried including pharmacological and non-pharmacological approaches. Concerning the pharmacological solutions, there is a vast array of literature on this topic, with numerous molecules being tested over the last years and only few having benefited from an in-depth evaluation. This includes amantadine hydrochloride, modafinil, pemoline, carnitine, and potassium channels blockers. Although all these drugs have demonstrated promising results in some studies, other works have failed to document any amelioration of fatigue and have thus questioned their place in the management of this symptom. Moreover, in a recent randomized, placebo-controlled, double-blind trial that compared the effects of amantadine, modafinil, and methylphenidate on MS fatigue, the studied drugs were not significantly superior to placebo in terms of efficacy and engendered more frequent adverse effects. Description of the mechanisms of action of these drugs and results of the corresponding studies falls outside the scope of this review [for more details, please refer to (1)].

In what concerns non-pharmacological alternatives, numerous therapies have been assessed so far and have led to some encouraging results, as has been demonstrated with exercise, whole body cryostimulation (53), cognitive behavioral therapies (CBT) (54), and NIBS (55). As mentioned in the introduction, in this review, we will only focus on the latter techniques (i.e., NIBS), the remaining does not match the main purpose of the current review.

As stated previously, tDCS is a NIBS technique that relies on the administration of a feeble electric current through two saline-soaked sponge electrodes, an anode and a cathode, placed on the scalp and connected to a battery-driven stimulator (28). The choice of the electrodes’ place and polarity depends on the intended effects. This approach has been shown to be beneficial in several neurological and psychological problems, such as neuropathic pain, anxiety, and depression, to set a few. Therefore, its application in PwMS, and particularly in the context of fatigue, has been the focus of several research teams. The majority of studies that assessed the effects of tDCS on subjective or perceived self-reported MS fatigue adopted a crossover randomized (or pseudorandomized) design, were double-blinded and sham-controlled, and consisted of applying an anodal stimulation over the left dorsolateral prefrontal cortex (DLPFC), the right posterior parietal cortex, the bilateral sensorimotor cortex, the bilateral motor, or the bilateral primary somatosensory cortex. The current used was of weak intensity, ranging from 1.5 to 2 mA; and the session duration varied between 15 and 20 min. While results from bilateral somatosensory cortex/bilateral motor cortex stimulation were encouraging (56–59); those of left DLPFC were controversial, with two studies showing negative results (60, 61) and two others documenting positive outcomes (62, 63). Such a discrepancy seems to be due to the difference in the current intensity [current intensity: 1.5 mA in (60) vs. 2 mA in (62, 63)] and the number of stimulation sessions [3 in (61) and 5 in (62, 63)] across the abovementioned studies. This point of view could be supported by the data of a recent work where robust anti-fatigue effects were seen after the left DLPFC and left M1 stimulation, with more lasting fatigue reduction observed following the former condition (64).

As for the posterior parietal cortex (62) and the bilateral sensorimotor cortex (of hand area) (57), results should be interpreted with caution since they are based on two studies only, and further investigations are needed before drawing any formal conclusion.

Regarding fatigability, cognitive and motor fatigability have been investigated in three studies, two of them tested the impact of one anodal session [over the right parietal cortex in (65) and over the left DLPFC in (66)] on cognitive performance during a particular task [visual task in (65), and measurement of P300 in (66)] and one work assessed the effects of 5 consecutive anodal sessions over M1 on a cluster of symptoms including pain, subjective fatigue, and motor fatigability (67). It has been shown that delivering anodal stimulation over the left DLPFC or the right parietal cortex could counteract cognitive fatigability and prevent decrement in cognitive performance (reflected by prolonged reaction time). On the other hand, anodal stimulation of M1 would result in a decrease in motor fatigability (of the contralateral leg), as well as an amelioration of subjective fatigue and pain.

All the previously reported studies have addressed the short-lasting effects of tDCS and its feasibility over a short period of time (sessions were performed over 1 or 2 weeks). However, to suggest this innovative technique as a therapeutic solution for PwMS, we need to maintain its effectiveness over time; such maintenance requires repetition of the sessions, and this has been addressed in some case studies where sessions (14–19 sessions) were repeated over 4 weeks and ensured a long-term reduction of fatigue and amelioration of cognitive functions as well as the mood state (68, 69).

Although the results of these trials are interesting, a limitation should be considered. In fact, health providers are dealing with a fragile population, thus suggesting to this population that recurrent traveling to the care facilities is a real challenge. Often, these patients are either disabled and/or have a busy personal or professional schedule, which should be taken into consideration. Hence, the best solution would be by organizing a home-based therapy. The feasibility and efficacy of the latter have been tested by Charvet et al., and it has been documented that remotely supervised tDCS sessions are safe, could be coupled with computer-based cognitive training programs, and would help in alleviating fatigue and improving cognitive performance (70).

Besides tDCS, other neuromodulation approaches have been also tried in the setting of MS fatigue. However, the literature is limited to few studies. Two of them have explored the potential role of transcranial random noise stimulation (tRNS) in the treatment of fatigue and three of them have evaluated the place of rTMS or TBS in this context.

Transcranial random noise stimulation yielded beneficial antifatigue effects in one study (71) but not in the other one (72). Compared to Palm and colleagues, Salemi and colleagues had a different study design (crossover vs. parallel arms, respectively),
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | IDCS/TRNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|-------------------|--------|---------------|-----------------|-----------------------------|-----------------|-----------------------------------------------|---------------------------------------------|----------------|---------|
| **tDCS studies** | | | | | | | | | | |
| Ferrucci et al. (59) | 25 (22 RR, 3 SP) Immunomodulant/immunosuppressive drugs: patients receiving treatment continued taking them during the study (without further information) | MFIS > 45 EDSS < 6.5 | Crossover double-blind, sham-controlled | Yes | 1 month | 5 consecutive daily sessions | Bilateral M1 | Anode: C3 and C4 Cathode: right deltoid | 1.5 mA and 20 min | FIS | Significant fatigue reduction up to 3 weeks after the last active stimulation session |
| Saiote et al. (60) | 25 (RR) Immunomodulant/immunosuppressive drugs: 10 patients receiving treatment | FSS ≥ 4 EDSS ≤ 6 | Crossover, double-blind, sham controlled | Pseudo randomization | 2 weeks | 5 consecutive daily sessions | Left DLPFC | Anode: F3 Cathode: contralateral forehead | 1.5 mA and 20 min | MFIS, FSS, MS-SF | Absence of fatigue improvement |
| Tecchio et al. (56) | 10 (7 RR, 1 SP, 2 PP) Immunomodulant/immunosuppressive drugs: Information NP | MFIS > 38 EDSS ≤ 3.5 | Crossover, double-blind, sham controlled | Yes | Please refer to # | 5 consecutive daily sessions | Bilateral whole body S1 | Anode: personalized Cathode: Oz | 1.5 mA and 15 min | MFIS | Significant decrease in fatigue scores up to 2 months following active condition. [The effects lasted up to 9.6+/- 3.6 weeks after the active condition (vs. 4.8+/- 1.8 weeks following sham condition)] |

(Continued)
TABLE 2 | Continued

| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | tDCS/rTNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|-------------------|--------|---------------|-----------------|-------------------------------|----------------|---------------------------------|-----------------------------------------------|----------------|---------|
| Tecchio et al. (57) | 21 (RR) Immunomodulant/immunosuppressive drugs: Information NP | Physical subscore of MFIS > 15 EDSS ≤ 3 | Crossover, double-blind, sham-controlled | Yes | Please refer to # | 5 consecutive daily sessions | Bilateral whole body S1 vs. bilateral hand SM area | Anode: personalized Cathode: Oz (S1 condition) vs. under the chin (SM condition) | 1.5 mA and 15 min | MFIS | Significant decrease in fatigue scores following active S1 condition (no changes after SM condition) |
| Hanken et al. (65) | Study 2: 46 (18 RR, 28 SP) Immunomodulant/immunosuppressive drugs: 67% receiving the treatment | NP | Parallel groups, double-blind, sham-controlled | Yes | NA | 1 session before the performance of a visual vigilance task | Right parietal cortex | Anode: P4 Cathode: left forehead | 1.5 mA and 20 min | RT on a visual vigilance task | Anodal right parietal stimulation counteracts the vigilance decrement. This effect was only observed in the setting of mild to moderate cognitive fatigue (and not in case of severe cognitive fatigue) | (Continued)
| Study | Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | tDCS/IRNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|-------|--------------|--------------------|--------|---------------|----------------|-------------------------------|-----------------|-----------------------------------------------|-----------------------------------------------|----------------|---------|
| Ayache et al. (68) | 16 (11 RR, 4 SP, 1 PP) Immunomodulant/immunosuppressive drugs: 13 patients receiving treatments | VAS (pain) > 4 | Crossover, double-blind, sham controlled | Yes | 3 weeks | 3 consecutive daily sessions | Left DLPFC | Anode: F3 Cathode: AF8 | 2 mA and 20 min | MFIS | No effects on fatigue (it is important to mention that fatigue was assessed as a secondary outcome) |
| Chalah et al. (62) | 10 (8 RR, 1 SP, 1 PP) Immunomodulant/immunosuppressive drugs: 10 patients receiving treatments | FSS > 5 EDSS ≤ 6.5 | Crossover, double-blind, sham controlled | Yes | 3 weeks | 5 consecutive daily sessions | Left DLPFC vs. Right PPC | Anode: F3 Cathode: AF8 vs. Anode: P4 Cathode: Cz | 2 mA and 20 min | MFIS, FIS and VAS | Significant fatigue reduction was obtained after left prefrontal cortex anodal stimulation but not after right parietal stimulation. Long-term effects were not assessed |
| Charvet et al. (70) | Study 1: 35 (20% RR in active arm, 75% RR in control arm) Study 2: 27 (40% RR in active arm, 58% RR in sham arm) Immunomodulant/immunosuppressive drugs: information NP | SDMT (z score) ≥ −3 EDSS?6.5 | Study 1: open label Study 2: parallel groups, double-blind, sham-controlled | Study 1: no sessions Study 2: yes | | | Left DLPFC | Anode: left prefrontal cortex Cathode: right prefrontal cortex (Exact position not precise) | 1.5 mA and 20 min (Intensity was set at 1.5 mA if 2 mA was not tolerated) | PROMIS FSS VAS | Study 1: no effect on fatigue Study 2: significant fatigue reduction which was more evident in patients with higher fatigue scores |

*Note: tDCS = transcranial direct current stimulation, IRNS = intracranial nerve stimulation, rTMS = repetitive transcranial magnetic stimulation, iTBS = intermittent theta-burst stimulation, DLPFC = dorsolateral prefrontal cortex, MFIS = Modified Fatigue Impact Scale, VAS = Visual Analog Scale, FSS = Fatigue Severity Scale, EDSS = Expanded Disability Status Scale, SDMT = Symbol Digit Modalities Test, PROMIS = Patient-Reported Outcomes Measurement Information System.
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | tDCS/trNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|-------------------|--------|---------------|------------------|-------------------------------|-----------------|---------------------------------|---------------------------------------------|----------------|---------|
| Fiene et al. (66) | 15 (14 RR, 1 SP) Immunomodulant/immunosuppressive drugs: All patients receiving treatments | WEIMuS ≥ 9 | Crossover, single blind, sham controlled | Yes | 1 week | 1 session | Left DLPFC | 1.5 mA and 27–28 min | VAS Simple RT P300 components (latency & amplitude) | Active stimulation session counteracted cognitive fatigue and prevented any decrease in task performance (reflected by an increase in P300 amplitude and a stabilization of the RT) |
| Cancelli et al. (59) | 10 (types NP) Immunomodulant/immunosuppressive drugs: information NP | MRIS >35 EDSS ≤ 2 | Crossover, double-blind, Sham-controlled, study | Please refer to # | 5 consecutive daily sessions | Bilateral whole body S1 | Anode: personalized Cathode: Oz | 1.5 mA and 15 min | MRIS | Significant fatigue reduction following active stimulation. |

(Continued)
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | tDCS/trNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|-------------------|--------|---------------|-----------------|------------------------------|----------------|---------------------------------|-----------------|-------------|---------|
| Chalah et al. (63) | 11 (10 RR, 1 SP) Immunomodulant/immunosuppressive drugs: 9 patients receiving treatments | FSS > 5 EDSS < 6.5 | Crossover, double blind, sham-controlled study | Yes | 3 weeks | Left DLPFC | Anode: F3 Cathode: F4 | 2 mA and 20 min | FSS and MFIS | Significant fatigue reduction (i.e., a decrease of MFIS scores) that persisted up to 1 week following the last active stimulation session |
| Mortezanejad et al. (64) | 32 (types NP) Immunomodulant/immunosuppressive drugs: information NP | FSS > 5 EDSS < 4 | Parallel groups, double blind, sham-controlled | NA | 6 sessions (3 sessions per week over two consecutive weeks, sessions were administered every other day) | Left DLPFC vs. Left M1 | For left DLPFC stimulation, anode over F3 and cathode over the contralateral supraorbital area For the left primary cortex, anode over C3 and cathode over C4 | 1.5 mA and 20 min | FSS | Significant fatigue reduction after active left DLPFC and after left M1 conditions. Only left DLPFC anodal stimulation led to long-lasting effects (up to 4 weeks following the last stimulation session) |
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | tDCS/rTNS electrodes* or rTMS/ITBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|--------------------|--------|---------------|-----------------|-------------------------------|----------------|--------------------------------|-----------------------------------------------|----------------|---------|
| Workman et al. (67) | 6 (RR) Immunomodulant/immunosuppressive drugs: information NP | NA | Crossover, double blind, sham-controlled study | Yes | NP | 5 daily consecutive sessions | Left M1 | Anode: M1 representation of the more-affected leg Cathode: contralateral supraorbital | 2 mA and 20 min | MFIS Motor task VAS (pain) | Improvement of fatigability, reduction of fatigue, and amelioration of pain |
| tRNS studies | | | | | | | | |
| Palm et al. (72) | 16 (11 RR, 4 SP, 1 PP) Immunomodulant/immunosuppressive drugs: 13 patients receiving treatments | VAS (pain) > 4 | Crossover, double blind, sham-controlled study | Yes | 3 weeks | 3 consecutive daily sessions | Left DLPFC | Anode: F3 Cathode: AF8 | 2 mA, random frequencies range 0–500 Hz and 20 min | MFIS | No effects on fatigue (It is important to mention that fatigue was assessed as a secondary outcome) |
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | IDCS/tRNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|-------------|------------------|--------|---------------|----------------|-------------------------------|----------------|---------------------------------|----------------------------------|----------------|---------|
| Saïemi et al. (71) | 17 (RR) Immunomodulant/immunosuppressive drugs: 13 patients receiving treatments | MFIS > 20 | Parallel, single-blind, sham-controlled study | NA | 10 sessions (5 consecutive daily sessions per week over 2 consecutive weeks) | M1 of the dominant side or contralateral to the most affected limb | C3 + FP2 or C4 + FP1 | 1.5 mA, random frequencies range 100–640 Hz and 15 min | MFIS | Significant fatigue reduction after the last session |
| Gaedje et al. (74) | 28 (26 RR, 2 SP) FSS ≥ 4 EDSS between 0 and 6 | Parallel, semi-blind, sham-controlled study | NA | 18 sessions (3 sessions per week over 6 weeks) | Left prefrontal cortex or bilateral M1 | Left prefrontal cortex: H coil 5 cm anterior to the left motor hotspot parallel to the sagittal suture M1: center of the H coil M1: | Left prefrontal cortex: 120% rMT, 18 Hz, 50 trains (train duration 2 s, ITI 20 s), 1,800 stimuli, 18 min M1: 90% rMT, 1 Hz, 40 trains, bursts of 20 stimuli, ITI 20 s, 800 stimuli, 18 min | FSS | Significant fatigue reduction mostly following M1 stimulation that lasted over 6 weeks |

(Continued)
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site | IDCS/RNS electrodes* or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|--------------------|--------|---------------|-----------------|------------------|----------------|--------------------------------|--------------------------------|----------------|---------|
| Korzhova et al. (75) | 34 (SP) Immunomodulant/immunosuppressive drugs: None | Modified Ashworth Scale ≥ 2 at the knee joint | Parallel, double-blind, sham-controlled study Concomitant physical therapy | Yes | NA | Bilateral M1 | Figure of eight coils positioned using neuronavigation and over bilateral M1 | rTMS: 80% rMT, 20 Hz, stimulation 2 s ITI 28 s, 1,600 stimuli, 30 min | MFS | Significant fatigue reduction |
| Mori et al. (73) | 30 (RR) Immunomodulant/immunosuppressive drugs: information NP (not modified 2 months prior and during the study) | EDSS between 2 and 6 Presence of lower limb spasticity | Parallel, double-blind, sham-controlled study: • iTBS alone • iTBS + exercise therapy • Sham stimulation + exercise therapy | Yes | NA | M1 leg area contralateral to the affected limb | Figure of 8 coils positioned over the optimal site evoking MEP on the contralateral soleus muscle vs. 1 cm ahead and 1 cm lateral to CZ if no detectable MEP at any leg | 80% aMT, 5 Hz, 10 bursts, three stimuli per burst at 50 Hz, repeated at 5 Hz, 600 stimuli, 200 s | FSS | Significant fatigue improvement following iTBS combined with exercise therapy, but not following iTBS alone (It is worth noting that fatigue was a secondary outcome) |

(Continued)
| Participants | Inclusion criteria | Design | Randomization | Washout interval | Number of stimulation sessions | Stimulation site or rTMS/iTBS coil position | Stimulation parameters and session duration | Fatigue measures | Results |
|--------------|-------------------|--------|---------------|------------------|-------------------------------|--------------------------------------------|---------------------------------------------|-----------------|--------|
| Korzhova et al. (75) | 34 (SP) Immunomodulant/immunosuppressive drugs: None | Modified Ashworth Scale ≥ 2 at the knee joint | Parallel, double-blind, sham-controlled study Concomitant physical therapy | Yes | NA | Bilateral M1 | iTBS: 80% rMT, 5 Hz, 10 bursts, three stimuli per burst at 35 Hz, repeated at 5 Hz, 1,200 stimuli, 10 min | MFIS | No changes in fatigue |
| Tramontano et al. (76) | 16 (9 SP, 7 progressive relapsing) Immunomodulant/immunosuppressive drugs: information NP | EDSS between 4.5 and 6.5 Modified Ashworth scale ≤ 1 at the leg | Parallel, double-blind, sham-controlled study Concomitant exercise-based vestibular rehabilitation | Yes | NA | Bilateral cerebellum | Two runs of iTBS over both the right and left cerebellum separated by a 5 min interval | FSS | Significant fatigue reduction following iTBS (It is worth noting that fatigue was a secondary outcome) |

aMT, active Motor Threshold; DLPFC, Dorsolateral Prefrontal Cortex; EDSS, Expanded Disability Status Scale; iTBS, Intermittent Theta Burst Stimulation; ITI, Intertrain Interval; FIS, Fatigue Impact Scale; FSS, Fatigue Severity Scale; M1, Primary Motor Cortex; MEP, Motor Evoked Potentials; MFIS, Modified Fatigue Impact Scale; MS-SF, Multiple Sclerosis-Specific Fatigue Scale; NA, Not Applicable; NP, Not Provided; PP, Primary Progressive; PPC, Posterior Parietal Cortex; PROMIS, Patient-Reported Outcomes Measurement Information System; rMT, resting Motor Threshold; RR, Relapsing Remitting; RT, Reaction Time; rTMS, repetitive Transcranial Magnetic Stimulation; S1, Primary Somatosensory Cortex; SM, Sensorimotor; SP, Secondary Progressive; tDCS, Transcranial Direct Current Stimulation; VAS, Visual Analog Scale. W EIMuS, Würzburger Fatigue Inventory for MS.

*Electrode positions are defined according to 10−20 EEG international system.

#Washout is considered completed when half of the tDCS effect is lost (i.e., in fact, MFIS was obtained each week following the last session of each block, when the MFIS increment met the criteria of the following formula: MFIS (washout time) − MFIS (before first session) < 0.5 (MFIS after the last session − MFIS before first session), it reflected the end of the washout period, the second block could then be administered).

§Sessions were combined with a computer-based cognitive training program.

Case reports are not included in this table.
applied a larger number of sessions (3 vs. 10, respectively), and targeted a different cortical site (left DLPFC vs. M1 of the dominant side or contralateral to the most affected limb, respectively).

Transcranial random noise stimulation/theta burst stimulation studies targeted different cortical sites and were applied alone or in combination with exercise or physical therapy. Some of these studies suggested promising findings that are worth replicating in future trials (73–76). Briefly, with regards to rTMS, 10–18 sessions applied at 5–20 Hz over M1 bilaterally, with or without physical therapy, resulted in significant fatigue reduction (74, 75). As for TBS, the existing literature on the matter consisted of iTBS protocols. Ten sessions of such intervention, combined with exercise or physical therapy, did not significantly affect fatigue when applied over the cerebellum or M1 bilaterally (75, 76) but yielded antifatigue effects when applied over M1 contralateral to the most spastic limb (73). The latter protocol applied without concomitant exercise did not significantly reduce fatigue compared to the sham (73). Here, it is worth stating that the considered iTBS studies primarily focused on MS spasticity, fatigue being included as a secondary outcome. Therefore, the effects of iTBS on primary MS fatigue merit to be further addressed. Details of NIBS application in MS fatigue are presented in Table 2.

CONCLUSION

This review explored the potential role of neurophysiology in the exploration and modulation of fatigue in PwMS. First, in terms of pathophysiology, the available studies that included intracortical excitability and corticospinal excitability outcomes yielded inconsistent findings. For instance, while fatigue was correlated with SICI/CSP (GABA-mediated outcomes) in some studies, such a correlation was not found in other studies. The included studies were cross-sectional; they assessed fatigue using different scales and included PwMS suffering from different disease subtypes. This highlights the relevance of longitudinally studying the dynamics of these parameters across the disease course and subtypes and their relationships with fatigue. In addition, considering secondary factors to fatigue and taking into consideration the symptom cluster in the covariate analysis would also be of help (3). Besides tackling the previously mentioned differences (subjected or perceived self-reported fatigue vs. fatigability, primary vs. secondary), the temporal dimension of fatigue merits to be considered. In this perspective, Palotai and colleagues longitudinally assessed PwMS and suggested different types of fatigue (sustained fatigue vs. one time-point fatigue vs. reversible fatigue), which seem to differ in brain imaging findings (brain parenchymal fraction, T2 lesion volume) (77), a finding that might also apply to corticospinal excitability parameters.

Second, in terms of tDCS, the data altogether suggest promising tDCS effects obtained on MS fatigue. The current challenge remains to find the best parameters to optimize treatment effects (e.g., applying a higher number of sessions, selecting the best cortical target, selecting the best return electrode location, designing patient-tailored electrodes, increasing the current intensity up to 4 mA) (56, 57, 68, 69, 78). As stated with neurophysiological exploration, it would be helpful to consider the temporal dynamics of fatigue and the symptom cluster when assessing the mediators of response to tDCS. It is noteworthy that, when it comes to either exploring or modulating MS fatigue using NIBS techniques, a confounder that needs to be considered or accounted for is the pharmacological profile of the recruited cohorts. For instance, some medications (e.g., disease-modifying therapies, symptomatic treatments) might modify the corticospinal excitability in PwMS (79). In addition, some treatments (e.g., sodium channel blockers, calcium channel blockers, medications that act on neurotransmitters pathways) may also affect the tDCS effects on corticospinal excitability (80). The relationship between the treatment status and the considered outcomes (e.g., SICI, ICF, IHI, CSP, or fatigue improvement) warrants further investigation since this was rarely or not tackled in previous studies.

Third, studying the effects of tDCS on corticospinal excitability would provide further insights into the neurophysiological mechanisms of fatigue and the antifatigue mechanisms of action of tDCS (57, 68).

Finally, home-based tDCS will provide a solution for physically disabled PwMS. The application of psychotherapies (e.g., CBT-based online interventions) and pharmacotherapy might yield synergistic effects (81). Such an approach constitutes a domain that remains to be explored in this context.

AUTHOR CONTRIBUTIONS

SA and MC: conceptualization and methodology. MC, NS, GA, and SA: data analysis, writing—original draft preparation, and writing—review and editing. SA: supervision. All authors have read and agreed to the published version of the manuscript.

REFERENCES

1. Ayache SS, Chalah MA. Fatigue in multiple sclerosis - insights into evaluation and management. Neurophysiol Clin. (2017) 47:139–71. doi: 10.1016/j.neucli.2017.02.004

2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. (2000) 343:938–52. doi: 10.1056/NEJM200009283431307

3. Ayache SS, Chalah MA. Fatigue and affective manifestations in multiple sclerosis—a cluster approach. Brain Sci. (2019) 10:10. doi: 10.3390/brainsci1001010

4. Chalah MA, Riachi N, Ahbab R, Créange A, Lefaucheur JP, Ayache SS. Fatigue in multiple sclerosis: neural correlates and the role of non-invasive brain stimulation. Front Cell Neurosci. (2015) 9:460. doi: 10.3389/fncel.2015.00460

5. Le H, Ken-Opurum I, Maculaitis M, Sheehan J. Comorbidity and economic burdens of fatigue among patients with Relapsing-remitting multiple sclerosis in the United States. [Poster Presentation]. MS Virtual 2020 Joint
ACRIMS-ECTRIMS meeting. Multiple Sclerosis Journal. Thousand Oaks, CA: SAGE (2020).

Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol. (2021) 21:468. doi: 10.1186/s12883-021-02036-1

Multiple sclerosis council for clinical practice guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America (1998).

Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM. (2008). 101:49–60. doi: 10.1093/qjmed/hcm122

Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler. (2009) 15:1509–17. doi: 10.1177/1352458509348519

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. (1989) 46:1121–3. doi: 10.1001/archneur.1989.00520460115022

Kos D, Nagels D, D’Hooghe MB, Duportail M, Kerckhoets E. A rapid screening tool for fatigue impact in multiple sclerosis. BMC Neurol. (2006) 6:27. doi: 10.1186/1471-2377-6-27

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:t727. doi: 10.31222/osf.io/v7gm2

van Kessel K, Obadia N, Antal A, Ayyah SE, Baeken C, Benninger DH, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. (2014) 125:2150–206. doi: 10.1016/j.clinph.2014.05.021

Lefaucheur JP, Ayyah SE, Baeken C, Benninger DH, Brunelin J, Cogianian F, et al. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). Clin Neurophysiol. (2017) 128:56–92. doi: 10.1016/j.clinph.2016.10.087

Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018). Clin Neurophysiol. (2020) 131:474–528. doi: 10.1016/j.clinph.2019.11.002

Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmöller J, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. Clin Neurophysiol. (2021) 132:269–306. doi: 10.1016/j.clinph.2020.10.003

Rossini PM, Berardelli A, Deuschl G, Halatta M, Märtens de Noordhout AM, Paulus W, et al. Applications of magnetic cortical stimulation. The international federation of clinical neurophysiology. Electroencephalogr Clin Neurophysiol. Suppl. (1999) 52:171–85.

Rossini PM, Burke D, Chen R, Cohen LG, Daskalakis Z, Di Jorio R, et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an IFCN Committee. Clin Neurophysiol. (2015) 126:1071–107. doi: 10.1016/j.clinph.2015.02.001

Groppa S, Oliviero A, Eiser A, Quarterone A, Cohen LG, Mall V, et al. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. (2012) 123:858–82. doi: 10.1016/j.clinph.2012.01.010

Coates KD, Aboudaroda SJ, Krüger RL, Martin T, Metz LM, Jarvis SE, et al. Multiple sclerosis-related fatigue: the role of impaired corticospinal responses and heightened exercise fatigability. J Neurophysiol. (2020) 124:1131–43. doi: 10.1152/jn.00165.2020

Mordillo-Mateos L, Soto-Leon V, Torres-Pareja M, Peina-Palomino D, Mendoza-Laz N, Alonso-Bonilla C, et al. Fatigue in multiple sclerosis: general and perceived fatigue does not depend on corticospinal tract dysfunction. Front Neurosci. (2019) 13:309. doi: 10.3389/fnscr.2019.00339

Lievre J, Mingers D, Heesen C, Bäumer T, Weiller C. Motor cortex excitability and fatigue in multiple sclerosis: a transcranial magnetic stimulation study. Mult Scler. (2005) 11:316–21. doi: 10.1177/13524585050511630a

Chaláh MA, Kauv P, Créange A, Hodel J, Lefaucheur JP, Ayyah SE. Neuropsychological, radiological and neuropsychophysiological evaluation of fatigue in multiple sclerosis. Mult Scler Relat Disord. (2019) 28:145–52. doi: 10.1016/j.msard.2018.12.029

Chaves AR, Kelly LP, Moore CS, Stefanelli M, Ploughman M. Prolonged cortical silent period is related to poor fitness and fatigue, but not tumor necrosis factor, in multiple sclerosis patients. Clin Neurophysiol. (2019) 130:474–83. doi: 10.1016/j.clinph.2018.12.015

Morgante F, Dattola V, Crupi D, Russo M, Rizzo V, Ghilardi MF, et al. Is central dysfunction. J Neurol Neurosurg Psychiatry. (2015) 86:274–9. doi: 10.1136/jnnp2015055805

Gruszka E, et al. Stimulated peripheral production of interferon-gamma is associated with raised inflammatory markers in multiple sclerosis. Mult Scler. (2009) 15:101–5. doi: 10.1177/1352458508093389

BMC Neurol. (2008). 101:49–60. doi: 10.1001/archneur.1989.00520460115022

Cowan DN, De Fazio S, Young CA, O’Brien MJ. Fatigue and multiple sclerosis: a disorder of movement preparation? J Neurol Neurosurg Psychiatry. (2011) 82:269–306. doi: 10.1136/jnnp2010.300585

Gold SM, Krüger S, Ziegler K, Krieger T, Schulz KH, Otte C, et al. Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry. (2011) 82:814–8. doi: 10.1136/jnnp2010.300209

Pokyrsko-Dragan A, Frydecka I, Kosmaczewa A, Ciszak L, Bilinska M, Grzeska E, et al. Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis. Clin Neurol Neurosurg. (2012) 114:1153–8. doi: 10.1016/j.clineuro.2012.02.048

Papuq E, Stelmasiak Z, Grieb P, Pawel G, Rejdak K. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neurosci Lett. (2010) 474:9–12. doi: 10.1016/j.neulet.2010.02.062

Constantinescu CS, Niegel P, Patterson M, Judd A, Braith M, Fahey AJ, et al. Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. J Neurol (2011) 307:127–31. doi: 10.1007/s00415-011-6224-z

Giovannoni G, Thompson AJ, Miller DH, Thompson EL. Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology. (2001) 57:676–81. doi: 10.1212/WNL.57.5.676

Adamszcz-Sowa M, Sowa P, Adamszcz J, Niedziela N, Misiolek H, Owczarek M, et al. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. J Physiol Pharmacol. (2016) 67:235-242.

Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. J Neurol (2011) 307:127–31. doi: 10.1007/s00415-011-6224-z

PETajan JH, White AT. Motor-evoked potentials in response to fatigueging exercise in multiple sclerosis patients. Clin Neurophysiol. (2000) 111:2188–95. doi: 10.1016/S1388-2457(00)00469-7
43. Perretti A, Balbi P, Oreificio G, Trojano L, Marcantonio L, Brescia-Morra V, et al. Post-exercise facilitation and depression of motor evoked potentials to transcranial magnetic stimulation: a study in multiple sclerosis. Clin Neurophysiol. (2004) 115:2188–33. doi: 10.1016/j.clinph.2004.03.028

44. Huang YZ, Rothwell JC, Chen RS, Lu CS, Chuang WL. The theoretical model of theta burst form of repetitive transcranial magnetic stimulation. Clin Neurophysiol. (2011) 122:1011–8. doi: 10.1016/j.clinph.2010.08.016

45. Conte A, Li Voti P, Pontecorvo S, Quattruccio ME, Baintone V, Rocchi L, et al. Attention-related changes in short-term cortical plasticity help to explain fatigue in multiple sclerosis. Mult Scler. (2016) 22:1359–66. doi: 10.1177/1352458516619780

46. Colombo B, Martellini Boneschi F, Rossi P, Rovaris M, Maderna L, Filippi M, et al. MRI and motor evoked potential findings in non-disabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol. (2000) 247:506–9. doi: 10.1007/s004150070148

47. Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callicco R, Cosi V. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler. (2004) 10:462–8. doi: 10.1191/1352458504ms1051oa

48. Santaronecchi E, Rossi S, Bartalini S, Cincotta M, Giovannelli F, Tatti E, et al. Neurophysiological correlates of central fatigue in healthy subjects and multiple sclerosis patients before and after treatment with amantadine. Neural Plast. (2015) 2015:616242. doi: 10.1155/2015/616242

49. Scheiddegger O, Kamm CF, Humpert SJ, Rösler KM. Corticospinal output during muscular fatigue differs in multiple sclerosis patients compared to healthy controls. Mult Scler. (2012) 18:1500–6. doi: 10.1177/1352458512438722

50. Thickbroom GW, Sacco P, Faulkner DL, Kermode AG. Asymmetry of brain excitability: a new biomarker that predicts objective and subjective symptoms in multiple sclerosis. Behav Brain Res. (2019) 359:281–91. doi: 10.1016/j.bbr.2018.11.005

51. Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Nourbakhsh B, et al. Transcranial direct current stimulation (tDCS) for fatigue in multiple sclerosis patients. A case-control study. Brain Stimul. (2016) 9:154. doi: 10.3389/fnins.2016.00147

52. Perretti A, Balbi P, Oreificio G, Trojano L, Marcantonio L, Brescia-Morra V, et al. Plasticity effects of neuromodulation against multiple sclerosis fatigue. Restor Neurol Neurosci. (2018) 34:1760–9. doi: 10.1177/1352458517732842

53. Korzhova J, Bakulin I, Sinitsyn D, Poydasheva A, Suponeva N, Zakharova I, et al. Impact of transcranial direct current stimulation on fatigue in multiple sclerosis: a randomized sham-controlled study. J Neurol. (2020) 278:1937–46. doi: 10.1007/s00702-020-08983-y

54. Chalah MA, Lefaucheur JP, Ayache SS. Long-term effects of tDCS on fatigue, mood and cognition in multiple sclerosis. Clin Neurophysiol. (2017) 128:2179–80. doi: 10.1016/j.clinph.2017.08.004

55. Zoghi M, Benecke R, Jansen JH, Hoffmann K. Effects of prefrontal tDCS on multiple sclerosis fatigue: a case study. Brain Stimul. (2017) 10:147. doi: 10.3389/fnins.2016.00154

56. Chalah MA, Lefaucheur JP, Ayache SS. Long-term effects of tDCS on fatigue. J Neurol Neuroimmunol. NeuroInflammation. (2017) 5:4. doi: 10.1123/NNI.2017.0052

57. Ayache SS, Lefaucheur JP, Chalah MA. Transcranial direct current stimulation: a glimmer of hope for multiple sclerosis fatigue? J Clin Neurosci. (2018) 55:10–12. doi: 10.1016/j.jocn.2018.06.002

58. Gaede G, Tiede M, Lorenz I, Brandt AU, Pfueller C, Dörr J, et al. Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue. J Neurol. (2014) 261:1552–8. doi: 10.1007/s00702-014-3777-9

59. Salemi G, Vazzoler G, Ragonesi P, Bianchi A, Cosentino G, Croce G, et al. Application of iTNS to improve multiple sclerosis fatigue: a pilot, single-blind, sham-controlled study. J Neural Rehabil. (2019) 126:795–800. doi: 10.1016/j.jnr.2019.03.006

60. Palum U, Chalah MA, Padberg F, Al-Ani T, Abdelloua M, Sorel M, et al. Effects of transcranial random noise stimulation (tRNS) on affect, pain and attention in multiple sclerosis. Restor Neurol Neurosci. (2016) 34:189–99. doi: 10.3233/RNN-150557

61. Mori F, Ljoka C, Magni E, Codecà C, Kusayanagi H, Monteleone M, et al. Transcranial magnetic stimulation for the treatment of a Multiple Sclerosis symptom cluster. Brain Stimul. (2020) 13:263–4. doi: 10.1016/j.brs.2019.09.012

62. Mora EP, Ljoka C, Magni E, Codecà C, Kusayanagi H, Monteleone M, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol. (2011) 258:1281–7. doi: 10.1007/s00415-011-5924-1

63. Gaede G, Tiede M, Lorenz I, Brandt AU. Pflüger C, Dörr J, et al. Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue. Neurology. (2017) 88:423–9. doi: 10.1212/WNL.000000000000423

64. Korzhova J, Bakulin I, Sinitsyn D, Poydasheva A, Suponeva N, Zakharova I, et al. Personalized, bilateral whole-body somatosensory cortex stimulation to relieve fatigue in multiple sclerosis. Eur J Neurol. (2019) 26:680–e44. doi: 10.1111/ene.13877

65. Tramontano M, Grosso MG, Soldi S, Casula EP, Bonni S, Mastrogiacomo S, et al. Cerebellar intermittent theta-burst stimulation combined with vestibular rehabilitation improves gait and balance in patients with multiple sclerosis: a preliminary double-blind randomized controlled trial. Cerebellum. (2020) 19:897–901. doi: 10.1007/s12311-020-01166-y
77. Palotai M, Cavallari M, Healy BC, Guttmann CR. A novel classification of fatigue in multiple sclerosis based on longitudinal assessments. *Mult Scler.* (2020) 26:725–34. doi: 10.1177/1352458519898112
78. Workman CD, Fietsam AC, Ponto LLB, Kamholz J, Rudroff T. Individual cerebral blood flow responses to transcranial direct current stimulation at various intensities. *Brain Sci.* (2020) 10:855. doi: 10.3390/brainsci10110855
79. Ayache SS, Chalah MA. Cortical excitability changes: a mirror to the natural history of multiple sclerosis? *Neurophysiol Clin.* (2017) 47:221–3. doi: 10.1016/j.neucli.2017.02.001
80. McLaren ME, Nissim NR, Woods AJ. The effects of medication use in transcranial direct current stimulation: a brief review. *Brain Stimul.* (2018) 11:52–8. doi: 10.1016/j.brs.2017.10.006
81. Chalah MA, Ayache SS. Noninvasive brain stimulation and psychotherapy in anxiety and depressive disorders: a viewpoint. *Brain Sci.* (2019) 9:82. doi: 10.3390/brainsci9040082

**Conflict of Interest:** SA declares having received compensation from ExoNeural Network AB, Sweden. MC declares having received compensation from Janssen Global Services LLC, ExoNeural Network AB, Sweden, and Ottobock, France.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ayache, Serratrice, Abi Lahoud and Chalah. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.